La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Bioxyne Bilan de santé

Santé financière contrôle des critères 6/6

Bioxyne has a total shareholder equity of A$2.7M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$4.7M and A$2.1M respectively.

Informations clés

Ratio d'endettement

AU$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	AU$1.53m
Fonds propres	AU$2.67m
Total du passif	AU$2.06m
Total des actifs	AU$4.74m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: BXN's short term assets (A$4.7M) exceed its short term liabilities (A$2.1M).

Passif à long terme: BXN has no long term liabilities.

Historique et analyse du ratio d'endettement

Niveau d'endettement: BXN is debt free.

Réduire la dette: BXN had no debt 5 years ago.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: BXN has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.

Prévisions de trésorerie: BXN is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.

Bioxyne Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 1.45 million.

Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 1.45 million.

New major risk - Market cap size

Bioxyne Limited Announces Retirement of N H Chua as Director

Bioxyne Limited, Annual General Meeting, Nov 17, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

Full year 2023 earnings released: EPS: AU$0.002 (vs AU$0 in FY 2022)

New minor risk - Financial data availability

Bioxyne Limited Appoints Jason Hine as Director

Bioxyne Limited (ASX:BXN) completed the acquisition of Breathe Life Sciences Pty Ltd.

First half 2023 earnings released

Bioxyne Limited (ASX:BXN) entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million.

Bioxyne Limited Announces Joining of Mr. Sam Watson the Board as Joint Chief Executive Officer

No independent directors

Paramount Star Investments Limited reached agreement to acquire 49% of Direct Selling Business of Bioxyne Limited from Bioxyne Limited (ASX:BXN) for $1 million.

Bioxyne Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2021)

Full year 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2021)

No independent directors

Bioxyne Limited Announces Board Changes

No independent directors

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)

Full year earnings released - AU$0.00093 loss per share

Full year earnings released - AU$0.0009 loss per share

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines